Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes for which there is currently no effective curative modality. Recent data suggest that hyperactivation of the tyrosine kinase SRC has a key role in MM development and therefore this kinase represents an important molecular target for MM therapy. We tested new pyrazolo [3,4-d]pyrimidine SRC inhibitors on a panel of MM cell lines expressing the active form of SRC. These SRC inhibitors exerted a significant proapoptotic effect on MM cells without affecting the normal mesothelial cell line MET-5A, supporting a possible use of these SRC inhibitors for a safe treatment of MM. We also showed that SRC inhibitor-induced apoptosis occurred concomitantly with an increase in the nuclear stability of the cyclindependent kinase inhibitor p27. This finding is remarkable considering that loss of nuclear p27 expression is a wellestablished adverse prognostic factor in MM, and p27 nuclear localization is crucial for its tumor-suppressive function. Consistently, SRC inhibition seems to promote the increase in p27 nuclear level also by inactivating the AKT kinase and downregulating cyclin D1, which would otherwise delay p27 nuclear import and provoke its cytoplasmic accumulation. To determine whether p27 stabilization has a direct role in apoptosis induced by SRC inhibition, we stably silenced the CDKN1B gene, encoding p27, in MSTO-211H and REN mesothelioma cells by transduction with lentiviral vectors expressing short hairpin RNAs against the CDKN1B transcript. Strikingly, p27 silencing was able to suppress the apoptosis induced by these SRC inhibitors in both MM cell lines, suggesting that p27 has a crucial proapoptotic role in MM cells treated with SRC inhibitors. Our findings reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in MM cells and provide a new rationale for the use of SRC inhibitors in MM therapy.
Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes for which there is currently no effective curative modality. Recent data suggest that hyperactivation of the tyrosine kinase SRC has a key role in MM development and therefore this kinase represents an important molecular target for MM therapy. We tested new pyrazolo [3,4-d] pyrimidine SRC inhibitors on a panel of MM cell lines expressing the active form of SRC. These SRC inhibitors exerted a significant proapoptotic effect on MM cells without affecting the normal mesothelial cell line MET-5A, supporting a possible use of these SRC inhibitors for a safe treatment of MM. We also showed that SRC inhibitor-induced apoptosis occurred concomitantly with an increase in the nuclear stability of the cyclindependent kinase inhibitor p27. This finding is remarkable considering that loss of nuclear p27 expression is a wellestablished adverse prognostic factor in MM, and p27 nuclear localization is crucial for its tumor-suppressive function. Consistently, SRC inhibition seems to promote the increase in p27 nuclear level also by inactivating the AKT kinase and downregulating cyclin D1, which would otherwise delay p27 nuclear import and provoke its cytoplasmic accumulation. To determine whether p27 stabilization has a direct role in apoptosis induced by SRC inhibition, we stably silenced the CDKN1B gene, encoding p27, in MSTO-211H and REN mesothelioma cells by transduction with lentiviral vectors expressing short hairpin RNAs against the CDKN1B transcript. Strikingly, p27 silencing was able to suppress the apoptosis induced by these SRC inhibitors in both MM cell lines, suggesting that p27 has a crucial proapoptotic role in MM cells treated with SRC inhibitors. Our findings reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in MM cells and provide a new rationale for the use of SRC inhibitors in MM therapy.
Introduction
Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes (pleura, peritoneum, tunica vaginalis testis and pericardium), whose principal risk factor is the exposure to asbestos (Robinson et al., 2005; Tsao et al., 2009) . Although originally MM was a rare cancer, the extensive use of asbestos during the twentieth century, together with its long-latency time (30-40 years following the first exposure), determined an increase in incidence, which is expected to peak over the period . At present there is no known curative modality for MM. The role of radical surgical resection is very controversial, because of the difficulties due to MM diffuse spreading and the high risk of perioperative morbidity and mortality. Radiotherapy or chemotherapy regimens have only limited effects. Although the recent introduction of newer agents, such as pemetrexed in combination with cisplatin, has shown a significant improvement in the patient quality of life, the prognosis remains extremely poor, with a median survival ranging between 9 and 17 months from diagnosis. For these reasons there is currently a great need to develop new effective therapeutic strategies.
Even though many different molecular alterations have been described in MM , the biological mechanisms underlying its development are not yet clarified. Understanding these mechanisms is essential to identify new targets for the development of more specific therapies.
Alterations in the activity of the non-receptor tyrosine kinase SRC are implicated in the development of several human cancers and, given its central role in regulating key processes in tumor development, such as proliferation, apoptosis, angiogenesis and invasion, this kinase is an important molecular target in cancer therapy (Yeatman, 2004) . Recent data show that SRC family kinases are hyperactivated in MM specimens and cell lines compared with normal mesothelial cells (Menges et al., 2010) . Moreover, SRC activation in MM samples correlates with a more advanced pathologic stage and the presence of metastasis. Conversely, SRC inhibition, mediated by the multitargeted tyrosine kinase inhibitor dasatinib, leads to apoptosis, cell cycle arrest and decreased migration and invasion in MM cell lines (Tsao et al., 2007) . Therefore, SRC proved to have a key role in MM development and represents an important therapeutic target.
We recently synthesized new pyrazolo [3,4-d] pyrimidine derivative SRC kinase inhibitors, binding the ATP pocket of the SRC kinase, which effectively inhibit SRC activity at nanomolar concentrations, as shown by enzymatic assays. These molecules functioned as excellent antiproliferative and proapoptotic agents in several tumor types (Schenone et al., 2010) . Here, we evaluated the effect of these new SRC inhibitors on a panel of human MM cell lines. We found that two of these molecules, in particular, were indeed able to inhibit SRC activation and reduce cell viability by induction of apoptosis. Interestingly, we found that SRC inhibition in mesothelioma cells induces, in different ways, an increase in the nuclear level of the cyclin-dependent kinase (CDK) inhibitor p27 (also known as KIP1 and encoded by CDKN1B), which is crucial for the apoptotic program triggered by these molecules.
Results and discussion
Cytotoxic effect of pyrazolo [3,4-d] pyrimidine derivative SRC inhibitors on MM cell lines We selected MM cell lines expressing the active form of SRC (phospho-SRC Tyr419) ( Figure 1a ) for treatment with five pyrazolo [3,4-d] pyrimidine derivative SRC inhibitors ( Figure 1b) . We treated the cell lines with the small molecules at concentrations ranging from 1.5 to 15 mM and after 72 h we evaluated cell viability by the MTS cell proliferation assay. The SRC inhibitors were also tested on the normal mesothelial cell line, MET5-A, in which SRC is inactive (Figure 1a) , to rule out possible cytotoxic effects of these molecules on non-neoplastic cells. We observed significant cytotoxic effects on MM cell lines with all molecules. S7, S29 and S35 proved to be effective only on specific cell lines (data not shown), whereas SI83 and SI91 resulted the most effective inhibitors for the greatest number of cell lines, without affecting normal mesothelial cells (Figure 1c ). It seems that in these MM cell lines the molecules that show a significant cytotoxic effect are also able to inhibit SRC phosphorylation, whereas the molecules that do not exert significant effects on cell viability do not achieve a significant phospho-SRC inhibition (data not shown). This could depend on different reasons, such as a different membrane penetration of the compounds in different cell lines. However, further studies are currently ongoing to better assess this issue. Given their greater effectiveness, we focused our further analyses on SI83 and SI91 (Figure 1d ), which showed their maximum efficacy on MSTO-211H and REN cell lines, according to their IC50 values (Figure 1e ).
To verify that SRC inhibitor effectiveness is dependent on the activation status of SRC, we also tested SI83 and SI91 on IST-MES1 and IST-MES2 cell lines, in which SRC is inactive. As expected, both molecules were ineffective on both these tumor cell lines (Figure 1c) .
To confirm that SI83 and SI91 inhibit SRC activation in MM cell lines, we evaluated the phosphorylation of SRC (Tyr419) 72 h after treatment at approximately their IC50 values. As expected, both molecules caused a strong decrease in phospho-SRC/total SRC ratio in all the cell lines tested (Figure 1f) . Moreover, MSTO-211H, NCI-H28 and NCI-H2052 also showed an increase in the level of total SRC upon treatment suggesting the existence of a positive feedback loop that may try to compensate for SRC inhibition. This is consistent to what reported in various tumor cell lines following treatment with other SRC inhibitors (Shor et al, 2007; Schweppe et al, 2009) .
SRC inhibitors induce apoptosis in MM cell lines
To evaluate the effect of our SRC inhibitors on cell cycle progression, we analyzed by FACS the cell cycle profile of MSTO-211H, REN and MET-5A cell lines 72 h after treatment with 7.5 mM SI83 and SI91. We observed only a slight accumulation in G 0 /G 1 phase of REN cells treated with SI83 and MET-5A cells treated with SI83 and SI91, but overall we did not find impressive significant effects of these SRC inhibitors (Figure 2a) . However, remarkably, the analysis showed the appearance of a sub-G 1 peak, which could be indicative of apoptosis, in MSTO-211H and REN cells following exposure to SI83 and SI91 but not in the normal mesothelial cell line MET-5A. Therefore, to confirm the ability of the SRC inhibitors to induce apoptosis in MM cell lines, we analyzed cell staining with an annexin V-FITC antibody and propidium iodide by FACS, following 72 h of treatment with 7.5 mM SI83 and SI91. Analyses of early and late apoptosis showed that both molecules were indeed able to induce significant levels of apoptosis in MSTO-211H and REN compared with MET-5A ( Figure 2b ).
Consistently, we observed a significant increase in the levels of the proapoptotic protein BAX (Figure 2c ) and in caspase-3 activity in both MSTO-211H and REN tumor cell lines 72 h after treatment with SI83 and SI91 ( Figure 2d ) with respect to MET-5A cells.
SRC inhibition increases p27 levels in MM cell lines by enhancing protein stability Interestingly, recent findings show that SRC can accelerate the proteasome-mediated proteolysis of p27 by its phosphorylation at Tyr74 and Tyr88 (Chu et al., 2007) . This is particularly intriguing, because reduced levels of p27 correlate with an adverse clinical outcome in several p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al tumor types, including MM, in which loss of nuclear p27 expression is a well-established adverse prognostic factor (Beer et al., 2001; Bongiovanni et al., 2001; Baldi et al., 2004) . Therefore, we analyzed the effect of SI83 and SI91 on p27 expression in MM cell lines. As expected, we observed a marked increase in p27 level in MSTO-211H and REN cells treated with the SRC inhibitors for 72 h, whereas only a slight increase of p27 was observed in MET-5A normal mesothelial cells ( Figure 3a ). Prof Giovanni Gaudino (Novara, Italy). Cells were cultured as recommended by the respective providers. REN were cultured as previously described (Bertino et al., 2008) . (a) Western blotting analysis of phospho-SRC Tyr419 (pSRC) and total SRC in MM cell lines. Equal amounts of proteins (70 mg) per sample were electrophoresed and blotted onto PVDF membranes (Thermo Scientific, Waltham, MA, USA). The membranes were incubated with antibodies against phospho-SRC (raised in rabbit to phosphorylated Tyr416, which corresponds to human Tyr419) and SRC (Cell Signaling, Danvers, MA, USA), following blocking in 3% BSA. The double bands observed in some cell lines can derive from phospho-SRC antibody cross-reaction with different members of the SRC family kinases, as previously suggested (Mezquita et al., 2010) and consistently to what reported in MM specimens (Menges et al., 2010) . The anti-b-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for a loading control. (b) Structure of the pyrazolo[3,4-d]pyrimidine derivative SRC inhibitors. These molecules were synthesized and purified as previously reported . (c) Effect of SI83 and SI91 on MM cell viability. The molecules were tested on MM cell lines expressing phospho-SRC (NCI-H2052, NCI-H28, MSTO-211H and REN), MM cell lines not expressing phospho-SRC (IST-MES1 and IST-MES2) and a normal mesothelial cell line (MET-5A). The molecules were dissolved in DMSO to a concentration of 20 mM and then diluted in culture medium before use. Cells were seeded in 96-well plates 24 h before treatment with the SRC inhibitors at concentrations ranging from 1.5 to 15 mM. Control cells were treated with DMSO at the maximum amount used to deliver the SRC inhibitors. Seventy-two hours after treatment, cell viability was evaluated by MTS assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega) following the manufacturer's instructions. The plates were subjected to spectrophotometric reading at two different wavelengths (540 and 630 nm). Results are reported as the means of three independent experiments, each conducted in triplicate, and expressed as percentages of cell viability (calculated with respect to control cells treated with DMSO alone). The absorbance values of treated and control samples were subjected to Student's t-test. Statistically significant differences are indicated with *Po0.05 (significant) or **Po0.01 (very significant). We also showed that DMSO at the maximum amount used to deliver the SRC inhibitors has no toxic effect on MM cell lines (Supplementary Figure S1) . p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al
To assess whether the rise in p27 levels observed in MM cells following SRC inhibition was indeed a consequence of its increased stability, we pre-treated MSTO-211H, REN and MET-5A cell lines with SI83 for 24 h and then added the translation inhibitor cycloheximide. We then evaluated p27 expression by western blotting at 0, 3, 6 and 10 h after exposure to cycloheximide. As shown in Figure 3b , SI83 stabilized p27 in MSTO-211H and REN cells, whereas only a slight increase in p27 stability was observed in MET-5A cell line. In particular, as calculated by linear regression, SRC inhibition increased the p27 half-life (t 1/2 ) from 5.52 to 12.8 h and from 6.6 to 17.24 h in MSTO-211H and REN cell lines, respectively. Conversely, in MET-5A, p27 t 1/2 only changed from 16 to 20.8 h. These results are consistent with the fact that p27 is mainly regulated at post-transcriptional level (Bloom and Pagano, 2003) and with the previous findings indicating that SRC affects p27 proteolysis (Chu et al., 2007) . Therefore, the marked increase in p27 stability after p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al treatment of MM cell lines with the SRC inhibitors is probably due to suppression of the proteasome-mediated proteolysis induced by SRC.
SRC inhibition increases p27 nuclear localization
In general, p27 loss provides a proliferative advantage to cancer cells and promotes disease progression. p27 has a crucial role in cell cycle control, mainly acting as a negative regulator of the G 1 -S transition by binding and inhibiting the cyclin E-CDK2 complex. Although this tumorsuppressive function of p27 is the best-characterized, p27 behaves as an atypical tumor suppressor and a regulator of key cellular processes, such as proliferation, motility and apoptosis, in both a positive and a negative manner depending on its subcellular localization (Chu et al., 2008) .
In quiescent normal cells p27 is located mainly in the nucleus, whereas in tumors it often accumulates in the cytoplasm. Cytoplasmic p27 supports the assembly and nuclear import of cyclin D-CDK4/6, thus promoting cell proliferation. Moreover, the cytoplasmic sequestration of p27 into complexes with cyclin D-CDK4/6 can contribute to cell cycle progression also by relieving cyclin E-CDK2 from p27 constraint (Sherr and Roberts, 1999) . Furthermore, cytoplasmic mislocalization of p27 seems to contribute to progression of many cancers also by increasing cell motility and metastasis and, importantly, inhibiting apoptosis (Blagosklonny, 2002; Coqueret, 2003; Wang et al., 2005; Chu et al., 2008) . Therefore, p27 has been defined as a nuclear tumor suppressor and a cytoplasmic oncogene. For this reason we set out to evaluate whether the SRC inhibitor-induced increase in p27 level occurred in a specific cellular compartment. Consistent with the cytoplasmic mislocalization of p27 in cancer cells, we observed a p27 cytoplasmic accumulation in untreated MSTO-211H and REN mesothelioma cells, whereas in MET-5A normal cells p27 was expressed at high levels in both the nucleus and cytoplasm (Figure 3c ). Since MET-5A are non-tumoral cells, the observed high p27 nuclear level was expected, whereas the p27 cytoplasmic expression is consistent with the proliferative activity of this SV40-immortalized cell line. Following SRC inhibition we observed an increase in p27 level in MSTO-211H and REN nuclei. In MSTO-211H cells we also observed a marked decrease in p27 cytoplasmic level. The increase in p27 nuclear/cytoplasmic ratio in both cell lines, which is consistent with the recent observation that SRC activation correlates statistically with a reduced nuclear p27 level in primary breast cancers (Chu et al., 2007) , suggests that SRC inhibition favors the p27 tumorsuppressive function in the nuclear compartment with respect to its cytoplasmic oncogenic role in MM cells.
SRC inhibitors inactivate AKT and downregulate cyclin D1 in MM cell lines SRC is also able to activate the survival pathway mediated by the AKT kinase (Chen et al., 2001) , whose hyperactivation has an important part in several human cancers, including MM . Moreover, AKT can phosphorylate p27 on Thr157, thus delaying its nuclear import (Liang et al., 2002) and facilitating its cytoplasmic sequestration into complexes with cyclin D-CDKs (Chu et al., 2008) , whereas AKT inhibition leads to p27 accumulation and nuclear localization (Motti et al., 2005; Yang et al., 2006) . This mechanism seems to function also in MM cell lines in which phospho-AKT inhibition mediated by the PI3 kinase inhibitor LY294002 induces an increase in p27 levels Mikami et al., 2010) and in its nuclear/cytoplasmic ratio (Supplementary Figure S2) . So, we looked at the effect of our SRC inhibitors on the activation of AKT and found, as expected, a marked decrease in the active form of AKT (phospho-AKT Ser473) in REN and MSTO-211H cells 72 h after treatment (Figure 3d ). This result suggests that the AKT inactivation owing to SRC inhibition might contribute at least in part to the observed increase in p27 nuclear level in REN and MSTO-211H cell lines. No significant alteration in AKT activation was observed in MET-5A non-tumoral cells. As reported above, cyclin D-CDK complexes are able to sequester, and thereby inhibit p27 in the cytoplasm (Sherr and Roberts, 1999) . Excessive cyclin D-CDK Figure 2 Apoptosis induction in mesothelioma cell lines treated with SI83 and SI91. (a) Representative cell cycle profiles showing the phase distribution of mesothelioma (MSTO-211H and REN) and normal mesothelial (MET-5A) cell lines treated with SI83 and SI91 molecules at the concentration of 7.5 mM. DMSO alone was added to untreated control cells at the same amount used to deliver the SI83 and SI91 molecules. Seventy-two hours after treatment, cells were harvested, washed with PBS and fixed in 70% ice-cold ethanol. Nuclei were stained with 5 mg/ml Propidium Iodide (PI) plus 20 mg/ml RNase (Sigma-Aldrich, St Louis, MO, USA) at 4 1C overnight in the dark and analyzed with a FACS Vantage s.e. Cell Sorter (Becton Dickinson, Mountain View, CA, USA). Data were analyzed using a Mod-Fit 3.2 cell cycle analysis software (Becton Dickinson). (b) A representative FACS analysis of apoptosis by annexin V-FITC and PI (Annexin V-FITC kit, Miltenyi Biotec Inc., Auburn, CA, USA). MSTO-211H, REN and MET-5A were treated with 7.5 mM SI83 and SI91 or DMSO for 72 h, then harvested and stained according to the manufacturer instructions. In the table are reported the values relative to early apoptosis (annexin V positive and PI negative) and late apoptosis (annexin V positive and PI positive). (c) Western blots with an anti BAX antibody (Santa Cruz Biotechnology) in MSTO-211H, REN and MET-5A treated for 72 h with SI83 and SI91 or DMSO. (d) Histograms showing caspase-3 activity in MSTO-211H, REN and MET-5A cell lines treated with SI83 and SI91 as described above. Caspase-3 enzymatic activity was determined in cellular lysates using the Colorimetric Caspase-3 Assay Kit (Sigma-Aldrich) following the manufacturer instructions. This assay is based on the hydrolysis of the peptide substrate acetyl-AspGlu-Val-Asp p-nitroanilide (Ac-DEVD-p-NA) by caspase-3, resulting in the release of the p-nitroaniline (pNA) moiety. The absorbance of pNA was measured spectrophotometrically at 405 nm by using a microplate reader. pNA pmols were determined by a calibration curve prepared with defined pNA solutions. Caspase-3 activity is expressed as pmol pNA/mg protein Â time (h). The reported values represent the means and s.d.'s of three separate experiments, each conducted in triplicate. Statistically significant differences between the treated cells and the control cells (exposed to DMSO alone) were evaluated by Student's t-test and indicated with **Po0.01 (very significant).
p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al expression and/or activity is a common event in human cancers (Ortega et al., 2002) . In MM, different molecular alterations lead to cyclin D overexpression or cyclin D-CDK hyperactivity (Kettunen et al., 2001; Lee et al., 2007) and a correlation between high cyclin D1 expression and decreased p27 level has also been shown . Consistent with the role of SRC in inducing cyclin D1 gene (CCND1) expression at the transcriptional level (Sinibaldi et al., 2000) , we observed a significant CCND1 mRNA downregulation in MSTO-211H and REN cells treated with SI83 and SI91 for 72 h (Figure 3e) , which was confirmed also at the protein level (Figure 3f) . Conversely, no significant alterations in cyclin D1 expression were observed in MET-5A non-tumoral cells (Figures 3e and f) .
Similar reductions in phospho-AKT and cyclin D1 levels in MM cells treated with dasatinib were previously reported (Tsao et al., 2007) . Here, we suggest that these reductions could represent another mechanism by which SRC inhibition affects p27, by counteracting the cytoplasmic accumulation of p27 and facilitating its nuclear tumor-suppressive activity.
Suppression of the SRC inhibitor-induced apoptosis by p27 silencing To determine whether p27 has a key role in the apoptosis induced by SRC inhibition, we stably silenced CDKN1B in MSTO-211H and REN cells by transduction with lentiviral vectors expressing short hairpin RNAs (Figure 4a) . Impressively, in p27-silenced cells the percentage of surviving cells following treatment with SRC inhibitors was markedly increased compared with p27 expressing cells (Figure 4b) . Moreover, p27 silencing completely abolished the SRC inhibitor-induced caspase-3 activation (Figure 4c ), suggesting that p27 is required for the apoptotic program triggered by SRC inhibitors in MM cells. As expected, SRC inhibition did not affect cell viability and caspase activity both in p27-expressing and p27-silenced MET-5A cells.
The role of p27 in apoptosis is still controversial, because some studies indicate that p27 overexpression may protect from apoptosis (Masuda et al., 2001 , Bravo et al., 2003 , whereas others show that its overerexpression causes apoptosis (Katayose et al., 1997; Wang et al., 1997) . One possible explanation could be that the p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al survival effects of p27 are cell-type specific (Coqueret, 2003) . Furthermore, as stated above, p27 regulates apoptosis in both a positive and a negative manner depending on its subcellular localization. Our data suggest that the SRC inhibitor-induced stabilization of p27 in the nuclei of MM cells could be responsible for the p27 proapoptotic role observed in this study. Interestingly, p27 stabilization, mediated by proteasome inhibition, induces apoptosis in oral squamous cell carcinoma cells (Kudo et al., 2000) . Treatment with a p27 antisense oligonucleotide can block apoptosis induced by proteasome inhibition, further supporting the existence and importance of a p27 proapoptotic role. These results are consistent with those obtained in our study showing induction of apoptosis promoted by a stabilization of p27, possibly due to inhibition of the SRC-induced proteolytic process mediated by the proteasome.
In the MM cell lines used in this study, p27 stabilization seems to be mainly related to apoptosis rather than to cell cycle arrest. These results are consistent with those previously reported by Wang et al. (1997) , showing that apoptosis triggered by p27 overexpression was not accompanied by cell cycle arrest. It has been suggested that cells arrested in G 1 might be protected from apoptosis (Katayose et al., 1997) . The role of p27 in apoptosis might be more important than its regulation of the G 1 -S transition, as suggested by the observation that cells from p27 knockout mice retain their ability to undergo G 1 arrest in response to growth inhibitory signals. However, these mice display multiple organ hyperplasia indicative of tissue overgrowth (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . Thus, it is possible that p27 serves an important physiological role in maintaining organ size through apoptosis induction.
The ability of SRC inhibitors to induce apoptosis rather than growth arrest in MM cells is particularly important for the development of new antitumoral therapies, considering that cell cycle arrest favors DNA repair and might interfere with the action of DNA damaging drugs, which represent the current therapeutic regimen for mesothelioma patients.
The observed induction of apoptosis following SRC inactivation in MM cells is consistent with the role of SRC in inhibiting this cell death process. Different mechanisms by which SRC inhibition could promote apoptosis have been identified, involving the regulation of caspase cascade (Cursi et al., 2006) and the control of both antiapoptotic (Karni et al., 1999) and proapoptotic (Yamaguchi et al., 2008) proteins. Here we observed a further mechanism, based on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in MM cells. Currently, the pathways by which p27 can Effect of SI83 on p27 stability in MSTO-211H, REN and MET-5A cell lines evaluated by western blotting after cycloheximide (CHX) exposure. Cells were treated either with 7.5 mM SI83 or DMSO as control. After 24 h, CHX (Sigma-Aldrich) was added to cells at the concentration of 100 mg/ml. At 0, 3, 6, 10 h following CHX addition, protein lysates were obtained and western blotting for p27 was performed. The density of the bands was quantified by densitometric analysis. Data are presented after normalization with the b-actin bands and reported as relative values with respect to the p27 density obtained before CHX exposure, at time 0. p27 half-life was calculated by linear regression. (c) Western blotting showing nuclear (N) and cytoplasmic (C) levels of p27 in MSTO-211H, REN and MET-5A cell lines 72 h after treatment with either 7.5 mM SI83 or DMSO. Nuclear extraction was performed as previously described (Faraonio et al., 2006) . The cytoplasmic fraction was collected after pelleting nuclei and cleared by centrifugation at 18 000 g for 15 min at 4 1C. Efficacy of nuclear-cytoplasmic separation was assessed using antibodies against nuclear (SP1) and cytoplasmic (b-tubulin) proteins (both from Santa Cruz Biotechnology). (Livak and Schmittgen, 2001) . CCND1 expression in controls is reported as 1, without any error bar, as indicated by Livak and Schmittgen (2001) . The s.d.'s of the CCND1 relative expression in treated samples are calculated from the s.d. of the DDCt values using the 'propagation of error' method. Statistical analysis was performed by subjecting the DCt values of treated and control samples to Student's t-test, as previously indicated (Yuan et al., 2006) . A P value o0.05 indicates that the DDCt is significantly different from 0. *Po0.05 (significant); **Po0.01 (very significant); ***Po0.001 (extremely significant). (f) Western blotting showing the changes in cyclin D1 protein level in MET-5A, MSTO-211H and REN cell lines treated with SRC inhibitors as described above. The anti-cyclin D1 antibody was purchased from Santa Cruz Biotechnology. The anti-b-actin antibody was used for a loading control. The density of the bands was quantified by densitometric analysis. Data are presented after normalization with the b-actin bands and reported as relative values with respect to the cyclin D1 density obtained for untreated controls, reported as 1.
p27-driven apoptosis in mesothelioma by SRC targeting P Indovina et al promote apoptosis are largely unknown and warrant further investigations.
In summary, we observed that our pyrazolo[3,4-d] pyrimidine derivative SRC inhibitors exerted a significant proapoptotic effect on MM cell lines, without affecting a normal mesothelial cell line, supporting a possible use of these SRC inhibitors for a safe treatment of MM. Moreover, we showed a new mechanism by which SRC inhibitors induce apoptosis in MM cells, dependent on an increase in the stability of p27 in the nuclear compartment. This finding is remarkable considering that loss of nuclear p27 expression is a wellestablished adverse prognostic factor in MM. Therefore, our observations provide a new rationale for the use of SRC inhibitors in MM therapy and suggest that p27 expression/localization could represent an useful end point for the evaluation of clinical trials based on the use of tyrosine kinase inhibitors affecting SRC.
To date, several studies have focused on the development of small molecules targeting SRC (Schenone et al., 2010) . Although currently we have not conducted studies comparing the effectiveness of these molecules with our SRC inhibitors in MM, we previously showed that PP2, a well-known SRC inhibitor, was less effective in inhibiting cell proliferation and in inducing apoptosis in different carcinomas compared with our compounds (Schenone et al., 2004; Carraro et al., 2006; Spreafico et al., 2008) . Recently, it has been suggested that targeting multiple tyrosine kinases could be more effective than inhibition of a single tyrosine kinase in MM treatment (Menges et al., 2010) . Future studies with our small molecules and other tyrosine kinase inhibitors will reveal which combinations provide the most effective and safe MM treatment. Ideally, it might be possible in the near future to evaluate patients for the status of SRC, its substrate p27 and other tyrosine kinases in order to adopt personalized therapeutic approaches.
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The authors declare no conflict of interest. Figure 4 Effect of p27 silencing on apoptosis induced by SRC inhibitors. MSTO-211H, REN and MET-5A cells were stably transduced with lentiviral vectors expressing a set of five short hairpin RNAs (shRNAs) against CDKN1B transcript (Mission shRNA, Sigma-Aldrich) and the non-target control (Mission non-target control, Sigma-Aldrich). Lentiviral vector preparation and infection was performed as previously described (Chiappetta et al., 2007) . The effect of SRC inhibition on cell viability and caspase-3 activity was evaluated in MSTO-211H, REN and MET-5A cells expressing p27 and not expressing p27 after treatment of these cell lines with 7.5 mM SI83 and SI91 for 72 h. Before performing caspase-3 assay, cells were counted with trypan blue and the obtained data were used to evaluate cell viability. The same cells were then lysed and subjected to caspase-3 assay. (a) Western blotting showing p27 inhibition in MSTO-211H, REN and MET-5A cells transduced with non-target shRNA and CDKN1B shRNA. (b) Histograms reporting the percentage of surviving MSTO-211H, REN and MET-5A cells expressing p27 (non-target shRNA) and not expressing p27 (CDKN1B shRNA) after treatment with SI83 and SI91. The percentages of surviving cells were calculated with respect to untreated controls (exposed to DMSO alone). The values represent the means and s.d.'s of four separate experiments. Statistically significant differences between cells expressing or not p27 were evaluated by Student's t-test and indicated with *Po0.05 (significant); **Po0.01 (very significant); ***Po0.001 (extremely significant). (c) Histograms reporting the caspase-3 activity in MSTO-211H, REN and MET-5A cells expressing p27 (non-target shRNA) and not expressing p27 (CDKN1B shRNA) after treatment with SI83 and SI91. The values represent the means and s.d.'s of three separate experiments, each conducted in triplicate. Statistically significant differences between treated and control cells (exposed to DMSO alone) were evaluated by Student's t-test and indicated with *Po0.05 (significant); **Po0.01 (very significant).
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